Biotechnology startup creator Flagship Pioneering is combining three of its portfolio companies—Etiome, Cellarity, and Empress Therapeutics—into a new venture called Etcelera. The merged company will use artificial intelligence and drug discovery tools to predict which experimental medicines might succeed in clinical trials.
GSK expects to nearly double the number of cancer medicines it is testing in clinical trials next year, according to a Wall Street Journal interview with a company scientist. The expansion follows a dealmaking spree as the British drugmaker accelerates its return to oncology.
Non-profit health system Bon Secours Mercy Health is in late-stage talks to acquire a majority stake in Surgery Partners, valuing the Bain Capital-backed surgical care provider at approximately $6 billion including debt.
Roche has entered into a global license and collaboration agreement with Zymeworks for ZW209, a trispecific T cell engager targeting DLL3 for lung cancer treatment. The deal includes $55 million upfront, up to $718 million in milestone payments, and tiered royalties on future sales.
Gilead Sciences will acquire PepStar Therapeutics' oral inflammation drug program, including an experimental IL-23 receptor inhibitor for inflammatory bowel disease, for $1.28 billion upfront in a deal that could compete with Johnson & Johnson's new immunology pill.
Swedish private equity firm EQT has agreed to acquire Dutch molecular testing company Qiagen for approximately €9.6 billion ($10.8 billion) in an all-cash voluntary public takeover offer at €46.50 per share, representing a 40.3% premium to the unaffected share price. The deal ends years of takeover speculation surrounding the diagnostics firm.
OpenAI has acquired Orchestra Bio, a startup building AI agents to help pharmaceutical companies manage drug development. The acquisition signals OpenAI's expansion into the healthcare sector, following rival Anthropic's similar moves.
Canada's Weston family, through holding company Wittington Investments, has agreed to acquire Britain's Boots pharmacy and beauty retail chain from Sycamore Partners and the Pessina family for $8.9 billion. The deal includes Boots' retail operations in the U.K. and Ireland, Boots Opticians, and the No7 Beauty Co.
Paramount Skydance reached settlements with California and 11 other state attorneys general who sued to block its proposed $110 billion acquisition of Warner Bros. Discovery. The settlement includes terms requiring 30 films annually and penalties for non-compliance.
A Texas judge approved a wind-down bankruptcy plan for CVS Health subsidiary Omnicare LLC following the sale of its business operations for $250 million and resolution of a nearly $1 billion judgment related to improperly dispensing prescription drugs.
Private equity firm Silver Lake is merging two of its French portfolio companies, business management software provider Cegid and payroll platform Silae, to create a European technology group valued at more than €10 billion ($11.6 billion). The deal comes as the software sector grapples with AI disruption.
The U.S. Department of Justice is expanding its antitrust investigation into Fox's $22 billion deal to acquire streaming platform Roku, with DOJ staff planning to seek additional information from the companies involved.
Connecting Excellence Group (XCE) has signed binding Heads of Terms for its first proposed recruitment acquisition, targeting a specialist UK and U.S. recruitment business that generated £1.79 million in earnings, as part of its strategy to use M&A to convert earnings into Bitcoin.
GoPro has been acquired and is shifting its business focus from consumer action cameras to defense, government, robotics and aerospace applications, with YouTuber Markiplier becoming the company's single largest shareholder.
Japanese Bitcoin treasury company Metaplanet agreed to invest 2,100 BTC (~$132.1M) plus $2.5M cash to acquire a 95.7% stake in Nasdaq-listed Super League Enterprise, establishing a US-based Bitcoin treasury platform.
Hewlett Packard Enterprise secured court approval for its settlement with the US Justice Department over its $14 billion takeover of Juniper Networks, defeating a challenge from Democratic state attorneys general who alleged the settlement was inadequate. The approval clears the path for the acquisition to close.
PTC Therapeutics won the bankruptcy auction for Sangamo Therapeutics' gene therapy assets with a $211 million bid. Sangamo filed for Chapter 11 bankruptcy in June after failing to find strategic alternatives.
Jazz Pharmaceuticals announced a definitive agreement to acquire privately-held Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments, gaining access to ABS-1230, an experimental treatment for KCNT1+ epilepsy, a rare inherited form of the disease with no approved therapies.
Tarsus Pharmaceuticals agreed to acquire privately-held Alkeus Pharmaceuticals for $450 million upfront and up to $800 million total, gaining gildeuretinol (ALK-001), a Phase 3 oral therapy for Stargardt disease. The rare genetic eye condition affects over 36,000 people in the U.S. and currently has no FDA-approved treatment, with pivotal trial data expected in late 2029.
Global investment firm KKR has signed a definitive agreement to acquire Medicover India, the Indian hospital business of Stockholm-based Medicover, in a deal valued at approximately $1.3 billion (₹10,000-14,250 crore). The acquisition marks KKR's largest healthcare deal in India and includes a 24-hospital network, with plans for additional investment of ₹3,000-4,000 crore for expansion.
Fortitude Mining Holdings, the Zcash mining subsidiary of Digital Currency Group, completed the acquisition of a 12.5 megawatt digital infrastructure facility in Prosser, Nebraska for $6.25 million in cash, with a net outlay of approximately $4.7 million after credits.
Supernus Pharmaceuticals and Indivior Pharmaceuticals announced an all-stock merger to create a combined company with approximately $2.2 billion in annual revenue and a portfolio of 11 commercialized medicines focused on neurological, psychiatric, and addiction-related conditions. The deal, described as a merger of equals, is expected to generate $125 million in cost savings.
Fanatics purchased BGC's Water Street Labs and CX Clearinghouse, gaining the ability to list and settle its own event contracts on a federally regulated platform. The deal positions Fanatics to compete directly with DraftKings and FanDuel in the rapidly growing prediction markets sector.
Payward, the parent company of cryptocurrency exchange Kraken, has acquired the embedded wallet business from Magic Labs, which is simultaneously undergoing a restructuring and rebranding to Newton Labs.
Samsung Biologics announced an all-cash tender offer to acquire Switzerland's PolyPeptide Group AG for CHF 1.46 billion ($1.8B), at CHF 44.31 per share — a 6.1% premium to last close and ~40% to the April 10, 2026 undisturbed price, marking South Korea's largest biopharma acquisition.
Payment processor Stripe and private equity firm Advent International have jointly offered to acquire PayPal Holdings for $60.50 per share, valuing the deal at approximately $53 billion. PayPal's stock surged 14-15% following the news.
Crypto exchange Bullish has agreed to acquire global transfer agent Equiniti in a $4.2 billion deal aimed at building tokenized securities infrastructure, marking a significant move toward traditional finance integration.
Tether has proposed merging NYSE-listed bitcoin treasury company Twenty One Capital with Strike and Elektron Energy, with Strike CEO Jack Mallers and Elektron founder Raphael Zagury taking executive roles. Twenty One Capital shares rose on the news.
MoonPay has acquired crypto key management firm Sodot in a $100 million stock deal and launched a new institutional business division led by former CFTC Acting Chair Caroline Pham. The acquisition provides security infrastructure for MoonPay's expansion into serving banks, asset managers, and trading firms.